<html>

<head>
<meta content="text/html; charset=utf-8" />


<title>UNITED STATES</title>



</head>

<body link=blue vlink=purple>



<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">UNITED STATES</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">SECURITIES AND
EXCHANGE COMMISSION</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Washington, D.C. 20549</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:16.0pt;">FORM 8-K</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">CURRENT REPORT</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">December 12, 2011</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><i><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Date of Report
(Date of earliest event reported)</font></i><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160; </font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:16.0pt;">Medytox Solutions, Inc.</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><i><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">(Exact name of registrant
as specified in its charter)</font></i></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Nevada</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><i><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">(State or Other
Jurisdiction of Incorporation)</font></i></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><i><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></i></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">000-54346</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><i><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">(Commission File
Number)</font></i></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><i><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></i></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">54-2156042</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><i><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">(IRS Employer
Identification No.)</font></i></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">400 S. Australian
Ave., Suite 800, West Palm Beach, Florida 33401</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><i><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">(Address of
Principal Executive Offices and Zip Code)</font></i></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;text-indent:.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">(561) 855-1626</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><i><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">(Registrant&#8217;s
Telephone Number, Including Area Code)</font></i></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:</font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-align:justify;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">[__]&#160;&#160;&#160;&#160;&#160; Written
communications pursuant to Rule 425 under the Securities Act </font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">(17 CFR 230.425)</font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">[__]&#160;&#160;&#160;&#160;&#160; Soliciting material
pursuant to Rule 14a-12 under the Exchange Act </font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (17 CFR 240.14a-12)</font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-align:justify;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">[__]&#160;&#160;&#160;&#160;&#160; Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-align:justify;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-align:justify;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">[__]&#160;&#160;&#160;&#160;&#160; Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-align:justify;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">____________________________________________________________________________</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">Section 1 &#160;Registrant&#8217;s
Business and Operations</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">Item 1.01 &#160;Entry into a
Material Definitive Agreement.</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;text-indent:.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">On
December 6, 2011, Medytox Solutions, Inc. (the &#8220;Company&#8221;) (OTCBB: &#8220;MMMS&#8221;)
entered into three material agreements with Valley View Drive Associates, LLC,
a New Jersey limited liability company (&#8220;Lender&#8221;). These agreements included a
promissory note (the &#8220;Note&#8221;) executed in connection with a $500,000 loan to the
Company; a convertible promissory note (the &#8220;Convertible Note&#8221;) executed in
connection with a separate $500,000 loan to the Company; and, a security
agreement (the &#8220;Security Agreement&#8221;), pursuant to which the Company and two of
its subsidiaries granted a security interest to Lender. Each of these
agreements is attached as an exhibit to this Form 8-K.</font></p>

<p style="margin:0in;margin-bottom:.0001pt;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Note
provides that the principal amount shall be repaid at the sum of $50,000 per
month with the first payment becoming due on March 30, 2012. Payment shall
thereafter be made on the last working day of each month for 10 months until
January 31, 2013. Interest on the outstanding principal balance of the Note
will be paid to the Lender at the rate of 20% per annum. All amounts due and
payable under the Note may be prepaid in whole or in part, at any time without
premium or penalty.&#160; In the event of a default by the Company under the terms
of the Note, any outstanding obligations under the Note may become due and
payable immediately. The Note is secured by a security interest in and lien
against the Company&#8217;s accounts receivable and all proceeds thereof, and the
accounts receivable and all proceeds thereof of two (2) of the Company&#8217;s
wholly-owned subsidiaries, Medytox Medical Management Solutions Corp. (&#8220;Medytox
MMSC&#8221;) and Medytox Institute of Laboratory Medicine, Inc.</font></p>

<p style="margin:0in;margin-bottom:.0001pt;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The
Convertible Note provides that the principal amount shall be repaid at the sum
of $50,000 per month with the first payment becoming due on March 31, 2012.
Payment shall thereafter be made on the last working day of each month for 10
months until January 31, 2013. Interest on the outstanding principal balance of
the Note will be paid to the Lender at the rate of 20% per annum. All amounts
due and payable under the Note may be prepaid in whole or in part, at any time
without premium or penalty. In the event of a default by the Company under the
terms of the Convertible Note, any outstanding obligations under the
Convertible Note may become due and payable immediately. The Convertible Note
is secured by a security interest in and lien against the Company&#8217;s accounts
receivable and all proceeds thereof, and the accounts receivable and all
proceeds thereof of Medytox MMSC and Medytox Institute of Laboratory Medicine,
Inc.</font></p>

<p style="margin:0in;margin-bottom:.0001pt;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin-bottom:12.0pt;margin-left:0in;margin-right:0in;margin-top:0in;text-indent:.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">Under the terms of the
Convertible Note, Lender has the right, at the Lender&#8217;s option, at any time
prior to the payment in full of all amounts due under such Convertible Note to
convert the principal and accrued and unpaid interest due and owing under such
Convertible Note, in whole or in part, into common stock of the Company (the
&#8220;Shares&#8221;) at an initial conversion price (the &#8220;Conversion Price&#8221;) of $2.50 per
share, subject to adjustment as further provided by the terms of the
Convertible Note.&#160; The number of Shares issuable upon conversion of the
Convertible Note shall equal the number obtained by dividing (a) the principal
amount of the Convertible Note to be converted plus accrued and unpaid interest
due thereon, by (b) the Conversion Price in effect on the date of conversion of
the Convertible Note, in whole or in part.</font></p>

<p style="margin:0in;margin-bottom:.0001pt;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">The Security
Agreement was executed by the Company and its subsidiaries, Medytox MMSC and
Medytox Institute of Laboratory Medicine, Inc. Pursuant to the Security
Agreement, the Company and the above identified subsidiaries each assigned,
pledged and granted to the Lender, a security interest in, and lien upon, all
of such entities&#8217; right, title, and interest in and to their respective
accounts receivable and the proceeds thereof.</font></p>

<p style="margin:0in;margin-bottom:.0001pt;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The descriptions
of the Note, the Convertible Note and the Security Agreement do not purport to be
complete and are qualified in their entirety by reference to the full text of
such documents which are filed as Exhibits. 10.1, 10.2 and 10.3 to this Current
Report on Form 8-K and which are incorporated herein by reference.</font></p>

<p style="margin:0in;margin-bottom:.0001pt;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">Section 2 &#8211; Financial
Information</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">Item 2.03 Creation of a
Direct Financial Obligation.</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">The information set forth
in Item 1.01 above is incorporated herein by reference.</font></p>

<p style="margin:0in;margin-bottom:.0001pt;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">2</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">____________________________________________________________________________</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">Section 9 &#8211; Financial
Statements and Exhibits</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">Item 9.01 Financial
Statements and Exhibits.</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">(d) Exhibits</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:1.0in;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">10.1 &#160;&#160;&#160;&#160;&#160;&#160; Promissory Note, dated as of December 6,
2011, by and between Medytox Solutions, Inc. and Valley View Drive Associates,
LLC </font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:1.0in;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:1.0in;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">10.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; Convertible Promissory Note dated as of
December 6, 2011, by and between Medytox Solutions, Inc. and Valley View Drive
Associates, LLC</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:1.0in;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:1.0in;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">10.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; Security Agreement dated as of December 6,
2011, by and between Medytox Solutions, Inc., Medytox Medical Management
Solutions Corp., Medytox Institute of Laboratory Medicine, Inc. and Valley View
Drive Associates, LLC</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">SIGNATURES</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; MEDYTOX
SOLUTIONS, INC.</font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">DATED:&#160;
December 12, 2011.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By:</font><u><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></u><i><u><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">/s/:&#160; William G.
Forhan</font></u></i><u><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></u></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; William
G. Forhan, CEO, CFO and Chairman,</font></p>

<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (Principal
Executive Officer)</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-align:center;text-indent:.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">(Principal Financial and
Accounting Officer)</font><b><font color=black face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;"> </font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-align:center;text-indent:.5in;"><b><font color=black face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">3</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">____________________________________________________________________________</font></b></p>




<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font color=black face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">EXHIBIT INDEX</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font color=black face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">Exhibit</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><u><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">Number</font></u></b></p>

<p style="margin:0in;margin-bottom:.0001pt;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;text-decoration:none;">&nbsp;</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">10.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; Promissory Note, dated as of December 6,
2011, by and between Medytox Solutions, Inc. and Valley View Drive Associates,
LLC</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">10.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; Convertible Promissory Note dated as of
December 6, 2011, by and between Medytox Solutions, Inc. and Valley View Drive
Associates, LLC</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-indent:-.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-indent:-.5in;"><font color=black face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">10.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">Security Agreement dated as of December 6, 2011, by and between Medytox
Solutions, Inc., Medytox Medical Management Solutions Corp., Medytox Institute
of Laboratory Medicine, Inc. and Valley View Drive Associates, LLC</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-indent:-.5in;"><font color=black face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-indent:-.5in;"><font color=black face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-indent:-.5in;"><font color=black face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">4</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">____________________________________________________________________________</font></b></p>

<p style="margin:0in;margin-bottom:.0001pt;margin-left:.5in;text-indent:-.5in;"><font color=black face="Times New Roman,serif" lang=EN-US style="font-size:10.0pt;">&nbsp;</font></p>



</body>

</html>
[{"type": "8-K", "sequence": "1", "filename": "msi8k121211.htm", "secsgml_size_bytes": 28381}]
{"company-data": {"conformed-name": "Medytox Solutions, Inc.", "cik": "0001374536", "assigned-sic": "8734", "irs-number": "542156042", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-54346", "film-number": "111256388"}, "business-address": {"street1": "400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR", "city": "WEST PALM BEACH", "state": "FL", "zip": "33401", "phone": "(561) 855-1626"}, "mail-address": {"street1": "400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR", "city": "WEST PALM BEACH", "state": "FL", "zip": "33401"}, "former-company": {"former-conformed-name": "CASINO PLAYERS, INC.", "date-changed": "20060905"}}
UNITED STATES
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
December 12, 2011
Date of Report
(Date of earliest event reported)
Medytox Solutions, Inc.
(Exact name of registrant
as specified in its charter)
Nevada
(State or Other
Jurisdiction of Incorporation)
000-54346
(Commission File
Number)
54-2156042
(IRS Employer
Identification No.)
400 S. Australian
Ave., Suite 800, West Palm Beach, Florida 33401
(Address of
Principal Executive Offices and Zip Code)
(561) 855-1626
(Registrant's
Telephone Number, Including Area Code)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
[__]      Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[__]      Soliciting material
pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[__]      Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[__]      Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)
____________________________________________________________________________
Section 1  Registrant's
Business and Operations
Item 1.01  Entry into a
Material Definitive Agreement.
On
December 6, 2011, Medytox Solutions, Inc. (the "Company") (OTCBB: "MMMS")
entered into three material agreements with Valley View Drive Associates, LLC,
a New Jersey limited liability company ("Lender"). These agreements included a
promissory note (the "Note") executed in connection with a $500,000 loan to the
Company; a convertible promissory note (the "Convertible Note") executed in
connection with a separate $500,000 loan to the Company; and, a security
agreement (the "Security Agreement"), pursuant to which the Company and two of
its subsidiaries granted a security interest to Lender. Each of these
agreements is attached as an exhibit to this Form 8-K.
The Note
provides that the principal amount shall be repaid at the sum of $50,000 per
month with the first payment becoming due on March 30, 2012. Payment shall
thereafter be made on the last working day of each month for 10 months until
January 31, 2013. Interest on the outstanding principal balance of the Note
will be paid to the Lender at the rate of 20% per annum. All amounts due and
payable under the Note may be prepaid in whole or in part, at any time without
premium or penalty.  In the event of a default by the Company under the terms
of the Note, any outstanding obligations under the Note may become due and
payable immediately. The Note is secured by a security interest in and lien
against the Company's accounts receivable and all proceeds thereof, and the
accounts receivable and all proceeds thereof of two (2) of the Company's
wholly-owned subsidiaries, Medytox Medical Management Solutions Corp. ("Medytox
MMSC") and Medytox Institute of Laboratory Medicine, Inc.
The
Convertible Note provides that the principal amount shall be repaid at the sum
of $50,000 per month with the first payment becoming due on March 31, 2012.
Payment shall thereafter be made on the last working day of each month for 10
months until January 31, 2013. Interest on the outstanding principal balance of
the Note will be paid to the Lender at the rate of 20% per annum. All amounts
due and payable under the Note may be prepaid in whole or in part, at any time
without premium or penalty. In the event of a default by the Company under the
terms of the Convertible Note, any outstanding obligations under the
Convertible Note may become due and payable immediately. The Convertible Note
is secured by a security interest in and lien against the Company's accounts
receivable and all proceeds thereof, and the accounts receivable and all
proceeds thereof of Medytox MMSC and Medytox Institute of Laboratory Medicine,
Inc.
Under the terms of the
Convertible Note, Lender has the right, at the Lender's option, at any time
prior to the payment in full of all amounts due under such Convertible Note to
convert the principal and accrued and unpaid interest due and owing under such
Convertible Note, in whole or in part, into common stock of the Company (the
"Shares") at an initial conversion price (the "Conversion Price") of $2.50 per
share, subject to adjustment as further provided by the terms of the
Convertible Note.  The number of Shares issuable upon conversion of the
Convertible Note shall equal the number obtained by dividing (a) the principal
amount of the Convertible Note to be converted plus accrued and unpaid interest
due thereon, by (b) the Conversion Price in effect on the date of conversion of
the Convertible Note, in whole or in part.
The Security
Agreement was executed by the Company and its subsidiaries, Medytox MMSC and
Medytox Institute of Laboratory Medicine, Inc. Pursuant to the Security
Agreement, the Company and the above identified subsidiaries each assigned,
pledged and granted to the Lender, a security interest in, and lien upon, all
of such entities' right, title, and interest in and to their respective
accounts receivable and the proceeds thereof.
The descriptions
of the Note, the Convertible Note and the Security Agreement do not purport to be
complete and are qualified in their entirety by reference to the full text of
such documents which are filed as Exhibits. 10.1, 10.2 and 10.3 to this Current
Report on Form 8-K and which are incorporated herein by reference.
Section 2 – Financial
Information
Item 2.03 Creation of a
Direct Financial Obligation.
The information set forth
in Item 1.01 above is incorporated herein by reference.
2
____________________________________________________________________________
Section 9 – Financial
Statements and Exhibits
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
10.1        Promissory Note, dated as of December 6,
2011, by and between Medytox Solutions, Inc. and Valley View Drive Associates,
LLC
10.2        Convertible Promissory Note dated as of
December 6, 2011, by and between Medytox Solutions, Inc. and Valley View Drive
Associates, LLC
10.3        Security Agreement dated as of December 6,
2011, by and between Medytox Solutions, Inc., Medytox Medical Management
Solutions Corp., Medytox Institute of Laboratory Medicine, Inc. and Valley View
Drive Associates, LLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
MEDYTOX
SOLUTIONS, INC.
DATED: 
December 12, 2011.                          By:
/s/:  William G.
Forhan
William
G. Forhan, CEO, CFO and Chairman,
(Principal
Executive Officer)
(Principal Financial and
Accounting Officer)
3
____________________________________________________________________________
EXHIBIT INDEX
Exhibit
Number
10.1        Promissory Note, dated as of December 6,
2011, by and between Medytox Solutions, Inc. and Valley View Drive Associates,
LLC
10.2        Convertible Promissory Note dated as of
December 6, 2011, by and between Medytox Solutions, Inc. and Valley View Drive
Associates, LLC
10.3
Security Agreement dated as of December 6, 2011, by and between Medytox
Solutions, Inc., Medytox Medical Management Solutions Corp., Medytox Institute
of Laboratory Medicine, Inc. and Valley View Drive Associates, LLC
4
____________________________________________________________________________